P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemiaKevin Lin, Kris C. Wood, Christopher F. Bassil et al.|Nature Cancer|2022Cited by 42
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting TherapiesAngela Su, Alexandre Puissant, Frank Ling et al.|Cancer Discovery|2020Cited by 26
A multiparametric niche-like drug screening platform in acute myeloid leukemiaReinaldo Dal Bello, Raphaël Itzykson, Justine Pasanisi et al.|Blood Cancer Journal|2022Cited by 13
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting TherapiesAngela Su, Alexandre Puissant, Frank Ling et al.|Blood|2019Cited by 5
Figure S6 from The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting TherapiesAngela Su, Alexandre Puissant, Frank W. Ling et al.|Unknown|2023Cited by 0